Trials / Completed
CompletedNCT00002632
Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Eastern Cooperative Oncology Group · Network
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic or recurrent salivary gland cancer.
Detailed description
OBJECTIVES: I. Estimate the response rate in patients with metastatic or recurrent salivary gland cancer treated with paclitaxel (Taxol, TAX) by 3-hour infusion. II. Describe the toxicity of TAX in these patients. OUTLINE: Single-Agent Chemotherapy. Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973. PROJECTED ACCRUAL: Up to 32 patients/histology will be entered. If no response is observed in the first 14 patients in a particular histology, accrual to that group will close; if after 18 months annual accrual is less than 10 patients/histology, accrual to that group may close.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paclitaxel |
Timeline
- Start date
- 1995-05-30
- Primary completion
- 2002-05-01
- First posted
- 2004-06-10
- Last updated
- 2023-06-15
Locations
29 sites across 2 countries: United States, South Africa
Source: ClinicalTrials.gov record NCT00002632. Inclusion in this directory is not an endorsement.